NASDAQ · PHARMACEUTICAL PREPARATIONS · MID CAP
Arcturus Therapeutics Holdings Inc. ARCT
8 fiscal years on record · USD · FY2025 reported · SEC filings only
Growth
USD 82.0M
Revenue, FY2025 · full 8-year series below
Revenue $M
Net income $M
FY2025 · Revenue 82.0 · Net income -65.8
Compound annual growth
Revenue compounded at +53.8% a year over five years.
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Profitability
−80 cents
lost on every revenue dollar
Operating margin
Net margin
FY2025 · Operating -93.0% · Net -80.2%
ROE
FY2025 · ROE -28.9%
Each USD of equity lost 29 cents this year.
The 8-year record
8 fiscal years
Every figure from documents filed with the SEC · USD
EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.
row low → row highnegative
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue $B | 0.1 | 0.2 | 0.2 | 0.2 | 0.0 | 0.0 | 0.0 | 0.0 |
| Operating income $B | −0.1 | −0.1 | −0.1 | 0.0 | −0.2 | −0.1 | −0.0 | −0.0 |
| EBITDA $B | · | · | · | · | · | · | · | · |
| Income tax $B | · | −0.0 | 0.0 | 0.0 | · | · | · | · |
| Net income $B | −0.1 | −0.1 | −0.0 | 0.0 | −0.2 | −0.1 | −0.0 | −0.0 |
| Free cash flow $B | −0.1 | −0.1 | −0.0 | 0.0 | −0.1 | −0.0 | −0.0 | −0.0 |
| EPS, diluted $ | −2.40 | −3.00 | −1.12 | 0.35 | −7.74 | −3.55 | −2.15 | −2.16 |
| Dividend / sh $ | · | · | · | · | · | · | · | · |
| Payout % | · | · | · | · | · | · | · | · |
| ROE % | −28.9 | −31.2 | −10.8 | 3.8 | −65.2 | −34.2 | −131.8 | −159.7 |
| Shares out B | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.02 | 0.01 |
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
Provenance
Company facts, as filed
How we verify · 0 failures in 32 reconciliationsAUDITED
Reconciled in 8 of 19 fiscal years. 44 checks could not be computed.
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2018